Premium
Intensified Downstream Processing of Monoclonal Antibodies Using Membrane Technology
Author(s) -
Nadar Sathish,
Shooter Gary,
Somasundaram Balaji,
Shave Evan,
Baker Kym,
Lua Linda H. L.
Publication year - 2021
Publication title -
biotechnology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.144
H-Index - 84
eISSN - 1860-7314
pISSN - 1860-6768
DOI - 10.1002/biot.202000309
Subject(s) - downstream processing , downstream (manufacturing) , monoclonal antibody , bioprocess , upstream (networking) , flexibility (engineering) , upstream and downstream (dna) , unit operation , computer science , engineering , chemistry , antibody , biology , operations management , immunology , economics , telecommunications , biochemistry , management , chemical engineering
The need to intensify downstream processing of monoclonal antibodies to complement the advances in upstream productivity has led to increased attention toward implementing membrane technologies. With the industry moving toward continuous operations and single use processes, membrane technologies show promise in fulfilling the industry needs due to their operational flexibility and ease of implementation. Recently, the applicability of membrane‐based unit operations in integrating the downstream process has been explored. In this article, the major developments in the application of membrane‐based technologies in the bioprocessing of monoclonal antibodies are reviewed. The recent progress toward developing intensified end‐to‐end bioprocesses and the critical role membrane technology will play in achieving this goal are focused upon.